Arrowhead’s Focus On Plozasiran Intensifies Competition With Ionis

Drug May Reach Market In 2025, After Olezarsen

Arrowhead’s in-house, late-stage cardiovascular disease programs will center on triglyceride-lowering plozasiran while it seeks a partner to fund Phase III for cholesterol-reducing zodasiran.

London, UK. 3rd January 2024. Horse racing events in the UK.
Targeting APOC3 is a two-horse race in hypertriglyceridemia • Source: Shutterstock

Arrowhead Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. both aim to bring their first wholly owned drugs to market for the treatment of familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), with Ionis’s olezarsen in the leading position. But Arrowhead outlined a new plan to focus all of its late-stage cardiovascular disease development efforts on its FCS and SHTG drug plozasiran, which means the company will seek a partner to pursue Phase III development of its other late-stage cardiovascular candidate, zodasiran.

Key Takeaways
  • Arrowhead will focus on its RNAi drug plozasiran for Phase III development but seek a partner for its other Phase III-ready cardiovascular disease candidate zodasiran.

    ...

Pasadena, CA-based Arrowhead outlined its Phase III program for plozasiran and revealed its partnering plan for zodasiran during a cardiometabolic research and development review on 25 June. The company reported...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Regeneron Wins PCSK9 Court Battle Against Amgen

 

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By 

As CEO Anderson backs high prices for innovative drugs in Europe

More from Therapy Areas

Gilead Ready To Go After Hepatitis D Again

 
• By 

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By 

The UK major's asthma drug gets a key expanded approval.